The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
All I've read on this board for the last 6 weeks is 'RNS needed tomorrow" or "we need an RNS or we'll crash back down". Relax guys, sit on your shares and let the wonderful team at Avacta continue to progress. They'll update the market in due course and I'm sure you can agree it'll be worth the wait. So no, we don't need an RNS tomorrow.
I've been invested here for about two months now. I think this week/next week is when we're going to start seeing some serious rerates, and I'm very excited. Firstly, an RNS to tell us how accurate our saliva test is and that it meets government requirements. Secondly, to announce manufacturing partners. Thirdly, a CE mark and FDA approval. And finally, sales figures. So many great milestones to look forward in the coming weeks and months ahead. Strap up, it's going to be a steep ride to the top.
I reckon we could see this close around £2 for the weekend with Stem news to follow the AGM and hopefully only a few weeks of ATM left! Been here for a while and happy to leave the 110's behind!!
You can literally click on my name and view my previous posts. Stop talking rubbish the both of you. Didn't realise so many children invest on AIM lol
Ok great, thank you very much Mardler. Very helpful information! So am I correct in assuming that if I apply for let's say 20% , they will allocate me as much as they possibly can e.g. 10%? It's not 'get filled for your complete order or get nothing' correct? Thanks
My point is if you're not responding to help then don't bother responding at all. Do you have anything useful to do with your time? Lol
I've been holding shares in Omega for about 6 weeks now, thank you very much. Noone is here to distract from anything. Pointless posts like yours take up unnecessary space on boards where people like myself can actually have learn things from.
I understand that but how do they decide who gets more? If lots of people apply for more than their allocation is it done on a first come first serve basis or?
13th July is what I understood from the RNS. Can you please confirm if that is correct? Thanks
No I can see the offer. I mean when will the shares be added to our account? Isn't there a specific date in July they're added? Also how does the applying for more work? Thanks
When do the new shares from the open offer hit our accounts? Also you can apply for more than your 5%. If the offer is under-subscribed does it work on a first come first serve basis? Many thanks in advance
Great words there Phoenix. I completely agree.
Thanks for your response. I appreciate the points you've made there. Yes, at Avacta's current price, if you're not happy to be invested for the longer-term and you're only in it for the Covid 19 play, I agree the risk may be much greater than with Odx (solely in terms of current market value). Having said that, I would feel much more comfortable holding my Avacta shares into the future much past this pandemic than I would Odx shares.
In regards to the placing done on the back of the Covid inflated share price, don't you think that's genius? Yes, it pi**ed a lot of shareholders off (including myself). But if you look at the bigger picture, it's only going to help the company move progress in other areas, at each step reaching value inflection points for its shareholders.
I agree the partnership with Medusa could have been announced at a later date. However, with the placing in mind and also chance of a leak, it made sense to announce as soon as it was confirmed.
The government today announced that it is looking at saliva tests, including Avacta's at The University of Southampton. I hope there will be some positive news to follow.
https://www.gov.uk/government/news/new-saliva-test-for-coronavirus-piloted-in-southampton
I complete disagree with most of your points regarding Avacta. I'm an investor here and there. The upside at Avacta is sevenfold, both in terms of their test (which if successful, will potentially be in demand multiple times over the odx test). Yes, there appears to be more risk of success in regards to their lateral flow Covid test, but they have a few other Covid plays & furthermore, a extremely bright future in the cancer market for a longer-term hold. There reason they've directed more funds that way, is to help accelerate clinical trials.
Avacta are looking for manufacturing partners. Odx are manufacturing. You cannot compare the two companies when both tests are completely different. Avacta's placing wasn't oversubscribed because people wanted to bet in for their lateral flow test. Conifer were in talks with Avacta well before Covid 19 and now they have invested at several times the price they started discussing at.
Also, please keep in mind the Boohoo owner who now has exclusive distribution rights for Avacta's lateral flow test surely knows what he's doing. Look at the success he's made of Boohoo. He wouldn't spend "substantial" money on setting up distribution for Avacta's test if he didn't see it happening. And if he was in it for a quick buck, he would have sold his shares by now, which he hasn't.
I'm not trying to hype Avacta at all. These are just my opinions. I just don't understand why people bash other companies on these boards. Is it an attempt to scare investors away from their holdings and buy here?
in its oncology. That is the reason
How do we go about purchasing the new shares? Any info would be appreciated. Thanks
Thought I'd just add this:
"1. What options is the government considering for collecting blood samples?
We are looking at three blood collection methods, and they will be assessed by PHE
in June and July. Those methods are – venous blood via phlebotomy, capillary
blood through a finger prick, and a blood spot on paper."
Agreed. It's a real shame. My investment in Tils has nothing to do with their Covid play. If anything that was just a bonus. I wonder what the share price would be if Tils never went down the Covid route.